APA-referens

Fang, S., Zhang, M., Wei, G., & Lu, K. (2017). Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. Oncotarget.

Chicago-stil citat

Fang, Shencun, Meiling Zhang, Guihong Wei, och Kai-Hua Lu. "Apatinib As a Third- or Further- Line Treatment in Patients With Advanced NSCLC Harboring Wild-type EGFR." Oncotarget 2017.

MLA-referens

Fang, Shencun, Meiling Zhang, Guihong Wei, och Kai-Hua Lu. "Apatinib As a Third- or Further- Line Treatment in Patients With Advanced NSCLC Harboring Wild-type EGFR." Oncotarget 2017.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.